Dorri Giv M, Bahreini Toosi M H, Aghamiri S M R, Akbari F, Taeb S
Radiology and Radiotherapy Department, Faculty of Paramedical, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Medical Physics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Biomed Phys Eng. 2016 Dec 1;6(4):220-234. eCollection 2016 Dec.
Much research has widely been conducted into thyroid hormones levels following radiotherapy for breast cancer. Consequently, in this study, we evaluated to relate the rate of thyroid hormones levels with the dose distribution among breast cancer patients.
Thirty patients were treated with 4-field breast cancer radiotherapy. The dose volume histograms, the volume percentage of the thyroid absorbing respectively 20, 30, 40 and 50 Gy were then estimated (V20, V30, V40 and V50) together with the individual average thyroid dose over the whole gland derived from their computed tomography-based treatment plans. Then, in serum samples triiodothyronine [T3], thyroxine [T4], thyroid-stimulating hormone [TSH] of the patients were measured before and after radiotherapy.
There were no significant differences in thyroid hormones levels before and after radiotherapy for patients with breast cancer (P value >.05).
On the balance, we understood that thyroid stimulating hormones levels did not change before and after cancer breast radiotherapy.
针对乳腺癌放疗后的甲状腺激素水平，已开展了大量广泛的研究。因此，在本研究中，我们评估了乳腺癌患者甲状腺激素水平与剂量分布之间的关系。
30例患者接受了四野乳腺癌放疗。随后，根据基于计算机断层扫描的治疗计划，估算了剂量体积直方图、甲状腺分别吸收20、30、40和50 Gy的体积百分比（V20、V30、V40和V50）以及整个腺体的个体平均甲状腺剂量。然后，在放疗前后测量患者血清样本中的三碘甲状腺原氨酸[T3]、甲状腺素[T4]、促甲状腺激素[TSH]。
乳腺癌患者放疗前后甲状腺激素水平无显著差异（P值>.05）。
总体而言，我们了解到乳腺癌放疗前后促甲状腺激素水平没有变化。
